Risk: Benefit profile of etanercept in elderly patients with rheumatoid arthritis, ankylosing spondylitis or psoriatic arthritis

被引:48
作者
Fleischmann, Roy [1 ]
Iqbal, Imran [1 ]
机构
[1] Univ Texas, SW Med Ctr, Dallas, TX 75235 USA
关键词
D O I
10.2165/00002512-200724030-00005
中图分类号
R592 [老年病学]; C [社会科学总论];
学科分类号
03 ; 0303 ; 100203 ;
摘要
Rheumatoid arthritis (RA), ankylosing spondylitis (AS) and psoriatic arthritis (PsA) are commonly thought of as inflammatory diseases that affect younger individuals. Although the initial presentation of these diseases is commonly in a patient's twenties or thirties, they usually persist for the duration of the patient's life. In addition, up to one-third of patients with RA have disease onset after 60 years of age. Older patients with any of these three diseases are more likely to have more severe disease with significant functional decline. They are also more likely to have co-morbid diseases and use concomitant medications than patients who are younger. In patients with RA, AS or PsA, the introduction of anti-tumour necrosis factor (TNF)-alpha therapies such as etanercept, infliximab and adalimumab has had a significant impact in ameliorating the signs and symptoms of disease, improving patient function and inhibiting radiographic progression. Anti-TNF alpha therapies now have well recognised safety profiles that have been demonstrated in the usual clinical trial populations for these diseases, but such populations under-represent patients >= 65 years of age. This review explores the information currently available regarding patients aged >= 65 years treated with anti-TNF alpha therapies for RA, AS or PsA, focusing on etanercept in RA because of a lack of data for other therapies and conditions. The analyses conducted show that there is similar efficacy in the treatment of RA in patients < 65 years old and those >= 65 years of age. Although there are some differences in the adverse events noted in these two age groups, it appears as though treatment of patients >= 65 years of age, compared with age-matched controls, is not dissimilar to treatment of patients < 65 years of age compared with their age-matched controls. Only by understanding the risks and benefits of therapy in the older age group can a true risk : benefit profile for etanercept, and ultimately other anti-TNF alpha therapies, be determined by the practising physician and the patient.
引用
收藏
页码:239 / 254
页数:16
相关论文
共 104 条
[1]   Socio-economic consequences of rheumatoid arthritis in the first years of the disease [J].
Albers, JMC ;
Kuper, HH ;
van Riel, PLCM ;
Prevoo, MLL ;
Van't Hof, MA ;
van Gestel, AM ;
Severens, JL .
RHEUMATOLOGY, 1999, 38 (05) :423-430
[2]   How to RECOVER from RENAISSANCE? The significance of the results of RECOVER, RENAISSANCE, RENEWAL and ATTACH [J].
Anker, SD ;
Coats, AJS .
INTERNATIONAL JOURNAL OF CARDIOLOGY, 2002, 86 (2-3) :123-130
[3]   Infliximab improves signs and symptoms of psoriatic arthritis: results of the IMPACT 2 trial [J].
Antoni, C ;
Krueger, GG ;
de Vlam, K ;
Birbara, C ;
Beutler, A ;
Guzzo, C ;
Zhou, B ;
Dooley, LT ;
Kavanaugh, A .
ANNALS OF THE RHEUMATIC DISEASES, 2005, 64 (08) :1150-1157
[4]   Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis - Results from the Infliximab Multinational Psoriatic Arthritis Controlled Trial (IMPACT) [J].
Antoni, CE ;
Kavanagh, A ;
Kirkham, B ;
Tutuncu, Z ;
Burmester, GR ;
Schneider, U ;
Furst, DE ;
Molitor, J ;
Keystone, E ;
Gladman, D ;
Manger, B ;
Wassenberg, S ;
Weier, R ;
Wallace, DJ ;
Weisman, MH ;
Kalden, JR ;
Smolen, J .
ARTHRITIS AND RHEUMATISM, 2005, 52 (04) :1227-1236
[5]   IMPACT OF DISABLEMENT DUE TO RHEUMATIC DISORDERS IN A BRITISH POPULATION - ESTIMATES OF SEVERITY AND PREVALENCE FROM THE CALDERDALE RHEUMATIC DISABLEMENT SURVEY [J].
BADLEY, EM ;
TENNANT, A .
ANNALS OF THE RHEUMATIC DISEASES, 1993, 52 (01) :6-13
[6]  
BARALIAKOS X, 2005, ARTHRITIS RHEUM S, V52, pS631
[7]  
Bathon JM, 2006, J RHEUMATOL, V33, P234
[8]   A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis [J].
Bathon, JM ;
Martin, RW ;
Fleischmann, RM ;
Tesser, JR ;
Schiff, MH ;
Keystone, EC ;
Genovese, MC ;
Wasko, MC ;
Moreland, LW ;
Weaver, AL ;
Markenson, J ;
Finck, BK .
NEW ENGLAND JOURNAL OF MEDICINE, 2000, 343 (22) :1586-1593
[9]  
Bingham CO, 2002, J RHEUMATOL, V29, P3
[10]   Direct and indirect costs of rheumatoid arthritis to an employer [J].
Birnbaum, HG ;
Barton, M ;
Greenberg, PE ;
Sisitsky, T ;
Auerbach, R ;
Wanke, LA ;
Buatti, MC .
JOURNAL OF OCCUPATIONAL AND ENVIRONMENTAL MEDICINE, 2000, 42 (06) :588-596